Evidence map›Paper›PMID 25855965›Full record

ArticleCell death & disease2015

Lysosomal ceramide generated by acid sphingomyelinase triggers cytosolic cathepsin B-mediated degradation of X-linked inhibitor of apoptosis protein in natural killer/T lymphoma cell apoptosis.

M Taniguchi, H Ogiso, T Takeuchi, K Kitatani, H Umehara, T Okazaki

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective.International journal of molecular sciences · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

M TaniguchiDepartment of Life Science, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan.ORCID 0000000159208285
H OgisoDivision of Hematology/Immunology, Department of Medicine, Kanazawa Medical University, 1-1 Daigaku Uchinada, Uchinada, Ishikawa 920-0293, Japan.
T TakeuchiDivision of Hematology/Immunology, Department of Medicine, Kanazawa Medical University, 1-1 Daigaku Uchinada, Uchinada, Ishikawa 920-0293, Japan.
K KitataniDepartment of Biobank, Tohoku Medical Megabank Organization, Tohoku University, 1-1 Seiryo, Aoba, Sendai 980-8574, Japan.
H UmeharaDepartment of Rheumatology and Clinical Immunology, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan.
T OkazakiDivision of Hematology/Immunology, Department of Medicine, Kanazawa Medical University, 1-1 Daigaku Uchinada, Uchinada, Ishikawa 920-0293, Japan.
Kanazawa Medical University · JPKyoto University · JPTohoku Medical Megabank Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that IL-2 deprivation induced acid sphingomyelinase-mediated (ASM-mediated) ceramide elevation and apoptosis in an NK/T lymphoma cell line KHYG-1. However, the molecular mechanism of ASM-ceramide-mediated apoptosis during IL-2 deprivation is poorly understood. Here, we showed that IL-2 deprivation induces caspase-dependent apoptosis characterized by phosphatidylserine externalization, caspase-8, -9, and -3 cleavage, and degradation of X-linked inhibitor of apoptosis protein (XIAP). IL-2 re-supplementation rescued apoptosis via inhibition of XIAP degradation without affecting caspase cleavage. However, IL-2 deprivation induced ceramide elevation via ASM in lysosomes and activated lysosomal cathepsin B (CTSB) but not cathepsin D. A CTSB inhibitor CA-074 Me and knockdown of CTSB inhibited ceramide-mediated XIAP degradation and apoptosis. Inhibition of ceramide accumulation in lysosomes using an ASM inhibitor, desipramine, decreased cytosolic activation of CTSB by inhibiting its transfer into cytosol from the lysosome. Knockdown of ASM also inhibited XIAP degradation and apoptosis. Furthermore, cell permeable N-acetyl sphingosine (C2-ceramide), which increases mainly endogenous d18:1/16:0 and d18:1/24:1 ceramide-like IL-2 deprivation, induced caspase-dependent apoptosis with XIAP degradation through CTSB. These findings suggest that lysosomal ceramide produced by ASM mediates XIAP degradation by activation of cytosolic CTSB and caspase-dependent apoptosis. The ASM-ceramide-CTSB signaling axis is a novel pathway of ceramide-mediated apoptosis in IL-2-deprived NK/T lymphoma cells.

Indexed as

ApoptosisCaspase 3Cathepsin BCell Line, TumorCeramidesCytosolHumansInterleukin-2Killer Cells, NaturalLymphoma, T-CellLysosomesSphingomyelin PhosphodiesteraseX-Linked Inhibitor of Apoptosis ProteinCaspase 3Cathepsin BCeramidesCTSB protein, humanInterleukin-2Sphingomyelin PhosphodiesteraseXIAP protein, humanX-Linked Inhibitor of Apoptosis Protein

Identifiers

PMID25855965
PMCPMC4650549
OpenAlexW1998308437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.